Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

scientific article

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1056/NEJM199903113401004
P698PubMed publication ID10072411

P2093author name stringSchuster M
Walsh TJ
Schwartz C
Finberg RW
Greenberg RN
Holcenberg JS
Pappas P
Arndt C
Seibel N
Bodensteiner D
Hiemenz J
Dummer S
P433issue10
P407language of work or nameEnglishQ1860
P921main subjectamphotericin BQ412223
P304page(s)764-771
P577publication date1999-03-01
P1433published inThe New England Journal of MedicineQ582728
P1476titleLiposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group
P478volume340

Reverse relations

cites work (P2860)
Q341146742002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer
Q43602550A 34-year-old man with lingual tumor. Lingual leishmaniasis in a patient with HIV infection
Q34335250A clinical perspective for the management of invasive fungal infections: focus on IDSA guidelines. Infectious Diseases Society of America
Q35987403A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK.
Q38049498A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients. Gruppo Italiano Malattie Ematologiche dell'Adulto, Gruppo Italiano Trapianto di Midollo Osseo, As
Q39328808A multicenter phase 2 study of empirical low-dose liposomal amphotericin B in patients with refractory febrile neutropenia.
Q40614209A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer
Q33922242A persistent challenge: the diagnosis of respiratory disease in the non-AIDS immunocompromised host
Q46200207A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT.
Q40612309A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group
Q34422191A species-specific approach to the use of non-antimony treatments for cutaneous leishmaniasis.
Q34294925A strategy for managing fungal infections in haematopoietic stem cell transplantation
Q35179541A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations.
Q33825563Advances in antimicrobial therapy
Q34312351Advances in treating acute myeloid leukemia
Q48202890Adverse effects of amphotericin B in children; a retrospective comparison of conventional and liposomal formulations
Q36042366Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis
Q83172302Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis
Q33874835Agents for treatment of invasive fungal infections
Q38872275AmBisome: relationship between the pharmacokinetic characteristics acquired by liposomal formulation and safety/efficacy
Q36826922Amphotericin B and coccidioidomycosis
Q44400535Amphotericin B and its lipid formulations
Q34294886Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.
Q34764830Amphotericin B and liver function
Q24187699Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function
Q38111293Amphotericin B formulations: a comparative review of efficacy and toxicity
Q24193811Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia
Q30887348Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia
Q34294904Amphotericin B preparations: a maximum tolerated dose in severe invasive fungal infections?
Q37854727Amphotericin B use in children: conventional and lipid-based formulations
Q46277655Amphotericin B used as a continuous infusion is safer.
Q40605942Amphotericin B--not so terrible
Q44527998Amphotericin B: time for a new "gold standard".
Q36724783An update on the use of antifungal agents
Q37684378Antifungal Therapy for Systemic Mycosis and the Nanobiotechnology Era: Improving Efficacy, Biodistribution and Toxicity
Q28080147Antifungal Therapy in Hematopoietic Stem Cell Transplant Recipients
Q38858839Antifungal agents and liver toxicity: a complex interaction
Q36111677Antifungal chemotherapeutics
Q34807486Antifungal drug resistance to azoles and polyenes
Q30653666Antifungal drugs in the treatment of systemic candidiasis: susceptibility to antifungal drugs, drug resistance, pharmacological data
Q37009912Antifungal management in cancer patients
Q34083129Antifungal pharmacodynamics: review of the literature and clinical applications
Q37727168Antifungal prophylaxis and treatment in patients with hematological malignancies
Q33289645Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study
Q35897495Antifungal therapy and outcomes in infants with invasive Candida infections
Q37421528Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update
Q36591360Antifungal therapy in febrile neutropenic patients: review of treatment choices and strategies for aspergillar infection
Q24239978Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections
Q24243629Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections
Q37873552Antifungal treatment strategies in patients with haematological diseases or cancer: from prophylaxis to empirical, pre-emptive and targeted therapy
Q33659379Antiinfectives update: focus on treatment and prevention of viral and associated infections
Q38202581Antimicrobial agents, drug adverse reactions and interactions, and cancer
Q88495615Análisis de Costo Efectividad de Estrategias de Tratamiento Antimicótico en Pacientes con Neutropenia Febril Persistente y Tratamiento Antibiótico de Amplio Espectro
Q38040820Are salt loading and prolonging infusion period effective in prevention of amphotericin B-induced nephrotoxicity?
Q33899108Aspergillosis in bone marrow transplant recipients.
Q35038459Aspergillosis. Pathogenesis, clinical manifestations, and therapy
Q35022494Aspergillus infections in allogeneic stem cell transplant recipients: have we made any progress?
Q36382134Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America
Q37641383Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex
Q89551883Breakthrough Bloodstream Infections Caused by Echinocandin-Resistant Candida tropicalis: An Emerging Threat to Immunocompromised Patients with Hematological Malignancies
Q34073422Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation
Q36463811Brief Report: Effects of Tenofovir and Amphotericin B Deoxycholate Coadministration on Kidney Function in Patients Treated for Cryptococcal Meningitis
Q40501860Brief report: practicability and safety of amphotericin B deoxycholate as continuous infusion in neutropenic patients with hematological malignancies
Q99566477Budget Impact of Microbial Cell-Free DNA Testing Using the Karius® Test as an Alternative to Invasive Procedures in Immunocompromised Patients with Suspected Invasive Fungal Infections
Q34237335Canadian clinical practice guidelines for invasive candidiasis in adults
Q42272295Candida infections in solid organ transplantation
Q42200421Candidaemia in patients with haematological disorders and stem cell transplant
Q36904887Candidemia in the in-patient setting: treatment options and economics
Q36158204Case-control study and case series of pseudohyperphosphatemia during exposure to liposomal amphotericin B.
Q34322081Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis
Q33998703Caspofungin for post solid organ transplant invasive fungal disease: results of a retrospective observational study
Q37888750Caspofungin: when and how? The microbiologist's view
Q35678997Changing strategies for the management of invasive fungal infections
Q57364560Chapter 9 Interaction of Polyene Macrolide Antibiotics with Lipid Model Membranes
Q34763371Characterization of the colloidal properties, in vitro antifungal activity, antileishmanial activity and toxicity in mice of a di-stigma-steryl-hemi-succinoyl-glycero-phosphocholine liposome-intercalated amphotericin B.
Q90737374Choosing the Right Antifungal Agent in ICU Patients
Q35905124Clinical Features and Prognosis of Invasive Pulmonary Aspergillosis in Korean Children with Hematologic/Oncologic Diseases
Q64070463Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B
Q34505582Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
Q40463769Clinical efficacy and tolerability of caspofungin in a renal transplant patient with Aspergillus flavus lung infection: case report.
Q51191494Clinical evaluation of a polymerase chain reaction assay to detect Aspergillus species in bronchoalveolar lavage samples of neutropenic patients.
Q32060480Clinical experience with itraconazole in systemic fungal infections
Q34546811Clinical hepatotoxicity associated with antifungal agents
Q37418841Clinical outcomes and prognostic factors of empirical antifungal therapy with itraconazole in the patients with hematological malignancies: a prospective multicenter observational study in Korea.
Q36968140Clinical pharmacology of antifungal agents in pediatric patients
Q35129039Clinical pharmacology of antifungal compounds
Q51617424Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America.
Q34936576Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.
Q35917135Combating infections in hematopoietic stem cell transplant recipients
Q46642455Combination antifungal therapy involving amphotericin B, rapamycin and 5-fluorocytosine using PEG-phospholipid micelles.
Q35974333Combination therapy for mucormycosis: why, what, and how?
Q34229980Comparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbits
Q34680675Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model
Q38696930Comparison between liposomal formulations of amphotericin B.
Q28359772Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial
Q40145641Comparison of micafungin and voriconazole as empirical antifungal therapies in febrile neutropenic patients with hematological disorders: a randomized controlled trial
Q41543803Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study.
Q45260686Comparison of the effect of amphotericin B desoxycholate and amphotericin B colloidal dispersion on renal functions and renal morphology in rats
Q34071600Concepts in design of comparative clinical trials of antifungal therapy in neutropenic patients
Q38284468Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.
Q38284463Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014.
Q38284458Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014.
Q37624898Continuous infusion of amphotericin B deoxycholate: an innovative, low-cost strategy in antifungal treatment.
Q44396642Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study
Q37263911Cost-effectiveness analysis comparing two approaches for empirical antifungal therapy in hematological patients with persistent febrile neutropenia
Q40487519Cost-effectiveness analysis of antifungal treatment for patients on chemotherapy
Q42165120Cost-effectiveness analysis of the empirical antifungal strategy in oncohaematological patients
Q48621980Cryptococcal meningitis in renal transplant patients associated with environmental exposure
Q37079099Current and future therapeutic options in the management of invasive aspergillosis
Q37030218Current antimicrobial usage for the management of neutropenic fever in Korea: a nationwide survey
Q37868705Current issues in the clinical management of invasive aspergillosis--the AGIHO, DMykG, ÖGMM and PEG web-based survey and expert consensus conference 2009.
Q32060457Current management of fungal infections.
Q37151326Current options in antifungal pharmacotherapy.
Q38115356Current research in empirical therapy for febrile neutropenia in cancer patients: what should be necessary and what is going on.
Q35019920Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades
Q37157893Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents
Q37833638Design issues in a randomized controlled trial of a pre-emptive versus empiric antifungal strategy for invasive aspergillosis in patients with high-risk hematologic malignancies
Q42646402Design of Micelle Nanocontainers Based on PDMAEMA-b-PCL-b-PDMAEMA Triblock Copolymers for the Encapsulation of Amphotericin B.
Q36484942Design of clinical trials of empiric antifungal therapy in patients with persistent febrile neutropenia: considerations and critiques
Q51191991Detection of Aspergillus species in blood and bronchoalveolar lavage samples from immunocompromised patients by means of 2-step polymerase chain reaction: clinical results.
Q89920309Development of Amphotericin B Micellar Formulations Based on Copolymers of Poly(ethylene glycol) and Poly(ε-caprolactone) Conjugated with Retinol
Q40041299Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).
Q37650317Diagnosis and treatment of fungal infections in allogeneic stem cell and solid organ transplant recipients.
Q38079194Diagnosis and treatment of invasive fungal infections focus on liposomal amphotericin B.
Q33753500Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1).
Q33722067Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B
Q39661366Differential transcriptional profiles induced by amphotericin B formulations on human monocytes during response to hyphae of Aspergillus fumigatus
Q38059082Disorders of calcium and magnesium balance: a physiology-based approach
Q45065480Drug-Induced Kidney Injury in the Elderly
Q80378913Drug-induced nephrotoxicity in children: pharmacologically based prevention of long-term impairment
Q38832223Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia.
Q40174281Economic evaluation of a preemptive treatment strategy for invasive fungal infection in neutropenic patients with hematological diseases
Q40333474Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden
Q37157379Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting
Q40497071Economic evaluation of intravenous itraconazole for presumed systemic fungal infections in neutropenic patients in Korea
Q36613885Economic evaluation of the prevention and management of systemic fungal infections in neutropenic patients
Q55034381Editorial response: choosing amphotericin B formulations-between a rock and a hard place.
Q46284853Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.
Q46366403Effects of hydration with salt repletion on renal toxicity of conventional amphotericin B empirical therapy: a prospective study in patients with hematological malignancies
Q57789799Efficacy and Safety of Low-Dose Liposomal Amphotericin B in Adult Patients Undergoing Unrelated Cord Blood Transplantation
Q40043040Efficacy and safety of amphotericin B formulations: a network meta-analysis and a multicriteria decision analysis.
Q30240770Efficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis.
Q37944001Efficacy and safety of current drug therapies for invasive aspergillosis
Q40313049Efficacy and safety of micafungin as an empirical antifungal therapy for suspected fungal infection in neutropenic patients with hematological disorders
Q53271427Efficacy and safety of micafungin for the prophylaxis of invasive fungal infection during neutropenia in children and adolescents undergoing allogeneic hematopoietic SCT.
Q44737751Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease
Q36456366Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study
Q43468516Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders
Q28345150Efficacy of TAK-457, a novel intravenous triazole, against invasive pulmonary Aspergillosis in neutropenic mice
Q33978902Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats
Q40190146Elderly kidney transplant recipient with intermittent fever: a case report of leishmaniasis with acute kidney injury during liposomal amphotericin B therapy.
Q34092228Emerging Issues in Nosocomial Fungal Infections
Q58690890Emerging Technologies of Polymeric Nanoparticles in Cancer Drug Delivery
Q36458402Emerging echinocandins for treatment of invasive fungal infections
Q44638978Empiric antifungal therapy in neutropenic cancer patients
Q37859365Empiric antifungal therapy in patients with febrile neutropenia
Q36285521Empiric treatment against invasive fungal diseases in febrile neutropenic patients: a systematic review and network meta-analysis
Q43834926Empiric versus preemptive therapy in the management of febrile neutropenia in the patient being treated for hematologic malignancy
Q37159577Empiric vs. preemptive antifungal treatment: an appraisal of treatment strategies in haematological patients
Q40489288Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin
Q40387020Empirical antifungal therapy in selected patients with persistent febrile neutropenia.
Q40492348Empirical antifungal therapy in selected patients with persistent fever and neutropenia
Q37379973Empirical voriconazole therapy for febrile neutropenic patients with hematological disorders: a prospective multicenter trial in Japan
Q80464838Endophthalmitis due to Trichosporon beigelii in acute leukemia
Q34606681Epidemiology of cryptococcal meningitis in the US: 1997-2009.
Q37925096European expert opinion on the management of invasive candidiasis in adults
Q46050924European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update
Q43415903Evaluating real-life clinical and economical burden of amphotericin-B deoxycholate adverse reactions
Q52312050Evaluation of Amphotericin B Lipid Formulations for Treatment of Severe Coccidioidomycosis.
Q38494920Evaluation of hypokalemia and potassium supplementation during administration of liposomal-amphotericin B.
Q35033597Evidence-based guidelines for empirical therapy of neutropenic fever in Korea
Q47263594Evolution and Clinical Translation of Drug Delivery Nanomaterials
Q36130619Experience with community-based amphotericin B infusion therapy
Q44738486Exposure of the yeast Candida albicans to the anti-neoplastic agent adriamycin increases the tolerance to amphotericin B.
Q59230857Factors Associated with Severe Manifestations of Histoplasmosis in AIDS
Q46447902Fatal amphotericin B overdose due to administration of nonlipid formulation instead of lipid formulation
Q34071620Febrile neutropenia in allogeneic transplantation
Q33265510Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia
Q31372000Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group
Q33253851Fungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents
Q37739908Fungal infections after hematopoietic stem cell transplantation
Q35038473Fungal infections in nontransplant patients with hematologic malignancies
Q34294869Fungal infections in patients undergoing blood and marrow transplantation
Q34145791Fungal infections in patients with neutropenia: challenges in prophylaxis and treatment
Q36569874Fungal pathogens and primary antifungal prophylaxis in patients with hematological malignancies: one year experience
Q36616182Fungal pneumonia due to molds in patients with hematological malignancies
Q34939981Fungicidal synergism of fluconazole and cyclosporine in Candida albicans is not dependent on multidrug efflux transporters encoded by the CDR1, CDR2, CaMDR1, and FLU1 genes.
Q59308866Galactomannan Does Not Precede Major Signs on a Pulmonary Computerized Tomographic Scan Suggestive of Invasive Aspergillosis in Patients with Hematological Malignancies
Q40497134Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study
Q42738330Galactomannan testing during mold-active prophylaxis
Q40114699Gastrointestinal Mucormycosis After Orthotopic Liver Transplantation Presenting as Femoral Nerve Palsy: A Case Report and Review of the Literature
Q91171836Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
Q33650105Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of Amer
Q34212799Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the
Q35746695Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections.
Q33420040Hematological toxicities associated with amphotericin B formulations
Q37016279High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study
Q79686756High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation
Q38507930How nanotechnology-enabled concepts could contribute to the prevention, diagnosis and therapy of bacterial infections
Q35245238Human Fungal Pathogens of Mucorales and Entomophthorales
Q36217734Hyperalgesia and Persistent Pain after Breast Cancer Surgery: A Prospective Randomized Controlled Trial with Perioperative COX-2 Inhibition
Q33748160Hypokalaemia-induced rhabdomyolysis after treatment of post-Kala-azar dermal Leishmaniasis (PKDL) with high-dose AmBisome in Bangladesh-a case report
Q40263137Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study
Q40481007Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study.
Q42946320Impact of the administration of liposomal amphotericin B in patients with renal function impairment at initiation of treatment
Q27336142Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis
Q40595108Improving efficacy of antifungal therapy by polymerase chain reaction-based strategy among febrile patients with neutropenia and cancer
Q35860053Incidence, Predictors, and Impact on Hospital Mortality of Amphotericin B Nephrotoxicity Defined Using Newer Acute Kidney Injury Diagnostic Criteria
Q46425791Induction of interleukin-1beta, tumour necrosis factor-alpha and apoptosis in mouse organs by amphotericin B is neutralized by conjugation with arabinogalactan.
Q35557446Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment
Q44571013Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
Q37791930Infectious complications in neutropenic cancer patients
Q34305085Infectious complications of febrile leukopenia
Q34348047Infectious morbidity in critically ill patients with cancer
Q40446187Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
Q44417476Intravenous Itraconazole followed by Oral Itraconazole for the Treatment of Amphotericin-B-Refractory Invasive Pulmonary Aspergillosis
Q37474433Intravenous itraconazole vs. amphotericin B deoxycholate for empirical antifungal therapy in patients with persistent neutropenic fever.
Q90482675Invasive Candidiasis in the Elderly: Considerations for Drug Therapy
Q38066616Invasive aspergillosis in the intensive care unit
Q36895540Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients
Q37631486Invasive candidiasis in pediatric intensive care units
Q38110850Invasive candidiasis: update on current pharmacotherapy options and future perspectives
Q37431764Invasive fungal infection in haematopoietic stem cell transplant recipients: epidemiology from the transplant physician's viewpoint
Q33234912Invasive fungal infections in neutropenic enterocolitis: a systematic analysis of pathogens, incidence, treatment and mortality in adult patients
Q44686777Invasive fungal infections in patients with hematologic malignancies: the next steps
Q34636544Invasive fungal infections: evolving challenges for diagnosis and therapeutics
Q34997741Invasive pulmonary aspergillosis: role of early diagnosis and surgical treatment in patients with acute leukemia
Q46908044Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities
Q40404772Is family screening necessary in brucellosis?
Q37287794Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome
Q47556262Leishmaniasis in humans: drug or vaccine therapy?
Q40647609Lethargy and vision loss: successful management of rhinocerebral mucormycosis
Q33723201Lipid amphotericin B combinations; 'la crème de la crème'?
Q44135235Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia
Q44733428Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients
Q44135232Lipid formulations of amphotericins: are you a lumper or a splitter?
Q33656455Lipid-based amphotericin B formulations: from animals to man.
Q34204648Lipid-based amphotericin B: a review of the last 10 years of use.
Q46373110Lipid-based amphotericin in pulmonary zygomycosis: safety and efficacy of high exposure in a renal allograft recipient
Q36868273Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions
Q45223612Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4.
Q28298468Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)
Q50793077Liposomal amphotericin B does not induce nephrotoxicity or renal function impairment in premature neonates.
Q43871855Liposomal amphotericin B for prophylaxis of invasive fungal infections in high-risk paediatric patients with chemotherapy-related neutropenia: interim analysis of a prospective study
Q46946844Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial).
Q34960317Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections
Q36140647Liposomal amphotericin B: clinical experience and perspectives
Q44033190Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: experimental studies in a murine model
Q37476694Liposomal vincristine for relapsed or refractory Ph-negative acute lymphoblastic leukemia: a review of literature
Q35592009Localised invasive sino-orbital aspergillosis: characteristic features
Q58852071Long term improvement in the treatment of canine leishmaniosis using an antimony liposomal formulation
Q40536892Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial
Q34280580Management of Candida species infections in critically ill patients
Q58791971Management of Invasive Fungal Infections in Adult Patients with Hematological Malignancies in Greece during the Financial Crisis: Challenges and Recommendations
Q38087195Management of chemotherapy-induced neutropenic fever
Q37909774Management of fungal lung disease in the immunocompromised.
Q35675979Management of infectious complications in the hematopoietic stem cell transplant recipient
Q35904821Management of invasive candidiasis in critically ill patients
Q36087577Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients
Q40533942Meta-analysis on safety and efficacy of liposomal amphotericin B in the empirical treatment of febrile neutropenia
Q34775518Micafungin compared with caspofungin for the treatment of febrile episodes in neutropenic patients with hematological malignancies: A retrospective study
Q40241173Micafungin for empirical antifungal therapy in patients with febrile neutropenia: multicenter phase 2 study.
Q40790252Micafungin in invasive fungal infections in children with acute leukemia or undergoing stem cell transplantation.
Q56970523Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial
Q37738437Modern antifungal therapy for neutropenic fever
Q40401842Modern antifungal therapy for neutropenic fever
Q34071591Modifications of therapy
Q37765079Modified intention to treat reporting in randomised controlled trials: systematic review
Q32068576Mortality and costs of acute renal failure associated with amphotericin B therapy
Q43681152Mortality rates in comparative trials of formulations of amphotericin B.
Q34443147Mucormycoses
Q37098160Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?
Q37401889NanoDisk containing super aggregated amphotericin B: a high therapeutic index antifungal formulation with enhanced potency
Q38628767Nanomedicine for Infectious Disease Applications: Innovation towards Broad-Spectrum Treatment of Viral Infections.
Q34230175Nanopharmaceuticals (part 1): products on the market
Q36441428Nationwide statistical analysis of myeloid malignancies in Korea: incidence and survival rate from 1999 to 2012.
Q56837353Need for Alternative Trial Designs and Evaluation Strategies for Therapeutic Studies of Invasive Mycoses
Q43712238Nephrotoxicity of amphotericin B desoxycholate
Q35627629New and emerging antifungal agents: impact on respiratory infections
Q45006383New antifungal agents and bronchopulmonary mycoses
Q38797864New facets of antifungal therapy
Q36491819Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations
Q49803837Non-Culture Diagnostics for Invasive Candidiasis: Promise and Unintended Consequences
Q46840248Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin
Q35220799Novel antifungal drugs against fungal pathogens: do they provide promising results for treatment?
Q50112710Optimization of voriconazole therapy for the treatment of invasive fungal infections in adults
Q37178176Optimizing efficacy of Amphotericin B through nanomodification.
Q36920328Optimizing efficacy of amphotericin B through nanomodification
Q37043539Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia
Q90470137Orbital apex syndrome secondary to aspergilloma masquerading as a paranasal sinus tumor: A case report and literature review
Q36425955Orbital mucormycosis in an immunocompetent individual.
Q35756513Outcome of Antifungal Combination Therapy for Invasive Mold Infections in Hematological Patients is Independent of the Chosen Combination
Q39883914Outcome of empirical or targeted antifungal therapy after antifungal prophylaxis in febrile neutropenia
Q37260918Outcomes associated with conventional versus lipid-based formulations of amphotericin B in propensity-matched groups
Q36163786PEGylated Phospholipid Micelle-Encapsulated Near-Infrared PbS Quantum Dots for in vitro and in vivo Bioimaging
Q50448386PEGylated liposomes associate with Wnt3A protein and expand putative stem cells in human bone marrow populations
Q37263189Patients at high risk of invasive fungal infections: when and how to treat
Q42255047Persistent hypokalemia in an acute lymphoblastic leukemia patient
Q35385786Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus
Q40455545Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever.
Q36759440Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia
Q38073334Pharmacoeconomic assessment of therapy for invasive aspergillosis
Q38097528Pharmacoeconomics of empirical antifungal use in febrile neutropenic hematological malignancy and hematopoietic stem cell transplant patients
Q37820674Pharmacoeconomics of voriconazole in the management of invasive fungal infections
Q34045435Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis
Q38681635Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Q34113512Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans
Q34352014Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection
Q33232599Pharmacological advances in the treatment of invasive candidiasis
Q36176371Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin
Q37732209Pharmacologically-induced metabolic acidosis: a review.
Q64070471Pharmacology of Liposomal Amphotericin B: An Introduction to Preclinical and Clinical Advances for Treatment of Life-threatening Invasive Fungal Infections
Q34768471Pharmacotherapy of Candida bloodstream infections: new treatment options, new era.
Q34113525Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate
Q82364250Polymerase chain reaction screening for fungemia and/or invasive fungal infections in patients with hematologic malignancies
Q37428678Population Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Children
Q36276870Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens
Q24542404Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases
Q39575509Posaconazole: an emerging therapeutic option for invasive rhino-orbito-cerebral mucormycosis.
Q40344144Positive Results of Serum Galactomannan Assays and Pulmonary Computed Tomography Predict the Higher Response Rate of Empirical Antifungal Therapy in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Q34532546Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
Q32052950Practice guidelines for lipid-based amphotericin B in stem cell transplant recipients
Q34460523Practice guidelines for the diagnosis and management of skin and soft-tissue infections
Q33894467Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America
Q92782666Pre-emptive versus empirical antifungal therapy in immunocompromised children
Q33371455Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC: data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry
Q64070466Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B
Q34511403Prevention of acute renal failure in the critically ill.
Q58772822Primary Oral Mucormycosis Due to Rhizopus microsporus after Allogeneic Stem Cell Transplantation
Q37657464Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome--still an open question?
Q35959480Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin: review of the literature
Q36248701Pseudohyperphosphatemia associated with high-dose liposomal amphotericin B therapy
Q44017071Pulmonary aspergillosis: diagnosis and treatment
Q36194915Pulmonary fungal infection with yeasts and pneumocystis in patients with hematological malignancy.
Q33974908Pulmonary infection caused by Gymnascella hyalinospora in a patient with acute myelogenous leukemia.
Q34350416Pulmonary reactions during treatment with amphotericin B: review of published cases and guidelines for management
Q34151170Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients.
Q35917383Recent advances in antifungal pharmacotherapy for invasive fungal infections
Q24642450Recent advances in the management of mucormycosis: from bench to bedside
Q58477139Recomendaciones para el tratamiento de la infección fúngica invasiva. Infeccion fúngica invasiva por Candida spp
Q26824260Recommendations for the Treatment of Invasive Fungal Infections in Hematological Malignancies: A Critical Review of Evidence and Turkish Expert Opinion (TEO-1)
Q38114270Recommendations for the management of candidemia in adults in Latin America. Latin America Invasive Mycosis Network.
Q93609063References
Q40562194Release of prostaglandin E-2 in bovine brain endothelial cells after exposure to three unique forms of the antifungal drug amphotericin-B: role of COX-2 in amphotericin-B induced fever
Q38236893Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?
Q46674198Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone
Q64131314Resumen de las recomendaciones terapéuticas para infecciones fúngicas en el paciente crítico no neutropénico: una visión multidisciplinar
Q40175242Retrospective Cohort Analysis of Liposomal Amphotericin B Nephrotoxicity in Patients with Hematological Malignancies
Q34098069Review of comparative studies between conventional and liposomal amphotericin B (Ambisome) in neutropenic patients with fever of unknown origin and patients with systemic mycosis
Q36531721Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients
Q38077678Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity.
Q35799730Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients
Q44925292Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis
Q40454115Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy.
Q35715408Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients
Q40271090Safety and efficacy of low-dose liposomal amphotericin B as empirical antifungal therapy for patients with prolonged neutropenia
Q33977852Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits.
Q73203964Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in beagle dogs
Q37613070Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients
Q45985382Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation.
Q33983629Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study
Q73755560Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): a 91-day study in rats
Q87393334Section 3: Prevention and Treatment of AKI
Q87393341Section 4: Contrast-induced AKI
Q33980413Single-dose AmBisome (Liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosis
Q35200641Specific infectious complications after stem cell transplantation
Q34071594Standard antifungal therapy in neutropenic patients
Q46881807Standard dosing regimen of liposomal amphotericin B is as effective as a high-loading dose for patients with invasive aspergillosis: AmBiLoad trial
Q34724824Study on the effect of neem (Azadirachta indica A. juss) leaf extract on the growth of Aspergillus parasiticus and production of aflatoxin by it at different incubation times
Q37473671Success rate and risk factors for failure of empirical antifungal therapy with itraconazole in patients with hematological malignancies: a multicenter, prospective, open-label, observational study in Korea
Q43115263Successful treatment of Aspergillus liver abscesses in a patient with acute monoblastic leukemia using combination antifungal therapy including micafungin as a key drug
Q43808662Successful treatment of invasive mould infection affecting lung and brain in an adult suffering from acute leukaemia
Q47230940Successful treatment of patients with respiratory failure due to fungal infection after allogeneic hematopoietic stem cell transplantation
Q40247785Successful treatment of pulmonary blastomycosis with continuously infused amphotericin B deoxycholate after failure with liposomal amphotericin B.
Q44516857Successful treatment of rhinocerebral mucormycosis with liposomal amphotericin B and surgery in two diabetic patients with renal dysfunction
Q33876645Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection.
Q35585219Systemic Antifungal Therapy: New Options, New Challenges
Q44606392Systemic antifungal agents
Q55437393T2 Magnetic Resonance Assay: Overview of Available Data and Clinical Implications.
Q34848032The Pathophysiology and Treatment of Candida Sepsis
Q32060501The cost of treating systemic fungal infections
Q43797281The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy
Q36264982The expenditures related to the use of antifungal drugs in patients with hematological cancers: a cost analysis
Q46593127The hepatotoxicity of antifungal medications in bone marrow transplant recipients
Q36344173The prevention of infection post-transplant: the role of prophylaxis, preemptive and empiric therapy
Q43600554The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylax
Q35193749The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project.
Q37800610The value of amphotericin B in the treatment of invasive fungal infections
Q44498477Therapeutic Approach to Candida Sepsis.
Q34214827Therapy for fungal infections in leukemia
Q40222438Tissue pharmacokinetics and pharmacodynamics of AmBisome® (L-AmBis) in uninfected and infected animals and their effects on dosing regimens
Q34022479Towards a targeted, risk-based, antifungal strategy in neutropenic patients
Q33409652Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B.
Q34228354Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin
Q34590013Treatment of documented and suspected neutropenia-associated invasive fungal infections
Q34667166Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update
Q37255172Treatment of invasive candidiasis in immunocompromised pediatric patients
Q38056762Treatment of invasive candidiasis in neutropenic patients: systematic review of randomized controlled treatment trials
Q37170218Treatment of invasive candidiasis in the elderly: a review
Q37469829Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
Q34273629Treatment of systemic fungal infections in older patients: achieving optimal outcomes
Q37863921Treatment strategies for invasive aspergillosis in neutropenic patients: voriconazole or liposomal amphotericin-B?
Q40800105Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML10). The MCR Childhood Leukaemia Working Party
Q44440957Triad of Acute Infusion‐Related Reactions Associated with Liposomal Amphotericin B: Analysis of Clinical and Epidemiological Characteristics
Q33852973Tuftsin-bearing liposomes in treatment of macrophage-based infections.
Q35794490Universal antifungal therapy is not needed in persistent febrile neutropenia: a tailored diagnostic and therapeutic approach
Q45017863Update on antifungal treatment of invasive Candida and Aspergillus infections
Q61832641Update on invasive fungal infections: the last two years
Q43191432Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine
Q37785548Updated guidelines for managing fungal diseases in hematology patients
Q36364856Use of antifungal drugs in hematology
Q43839758Use of liposomal amphotericin B in the treatment of disseminated coccidioidomycosis
Q44589171Voriconazole for invasive aspergillosis in oncohematological patients: a single-center pediatric experience
Q33946021Voriconazole: the newest triazole antifungal agent
Q33712955Weekly high-dose liposomal amphotericin B (L-AmB) in critically ill septic patients with multiple Candida colonization: The AmBiDex study
Q73230080[Invasive fungal infections in patients with hematological malignancies: a clinical approach]
Q32105170[New lipid formulations of amphotericin B. Review of the literature].

Search more.